Hope the buys keep coming as the day progresses2 Jul 2019 12:12
The biotech and pharmaceuticals firm reported a pre-tax loss of £2.7mln for the period, almost £1mln less than the £3.6mln loss reported a year ago, while it ended the period with cash and cash equivalents of £5.6mln, compared to £7.9mln previously.
READ: e-Therapeutics and C4X Discovery to collaborate on Parkinson's Disease treatment
In its outlook, the company said it was likely there would be a further reduction in its operating losses in the second half of the year, reflecting an ongoing cost reduction plan and anticipated lower spend on two core drug discovery projects.
The firm added that based on financial projections and current funding, it would remain financed into 2020.
Post-period, e-therapeutics said it had filed a new patent covering breakthroughs in the computational approach of its NDD platform.
The NDD is a computer platform that uses data mining and artificial intelligence (AI) to identify compounds that could potentially disrupt the progression of a disease, helping to develop better treatments